TYRA-300
In human trialsHeight trial running, no resultBy mouthSmall moleculeAlso dabogratinib
A pill built to block only the receptor that slows cartilage growth, and not its relatives.
Oral FGFR3-selective inhibitor, designed to avoid the toxicities of FGFR1, FGFR2 and FGFR4 inhibition. In cancer trials, and in a phase 2 trial in children with achondroplasia.
Risks. Three adults with advanced cancer reported from its first trial had no severe side effects. Avoiding the harms of related drugs is what it was built for, not something a trial has shown.
On this page
- At the growth plate, members only
- Risks and side effects, members only
The rest of this page is for members
What has been measured, in whom, with every source, and what it does to the rest of you. And every article in the library.
Join for $11.99Lifetime · 3 of 10 founding spots left
Tax is added at checkout (VAT/GST where it applies).
Renews every month at the current price plus tax until you cancel. Cancel from your account before the next monthly charge to stop it.
Card purchases are sold and charged by Link (Stripe) under Link's terms and refund policy.
Already a member? Sign in
Educational content, not medical advice. Nothing here is a recommendation to take or stop taking anything — talk to a doctor about your own situation.